FDA approved studies are yielding transformative results for psychedelics as medicine to treat a wide range of mental and physical health conditions. Within the last couple of years, the prospect of cures for treatment-resistant diseases, such as major depression, PTSD, and addiction, is racing toward reality with a handful of pioneering companies and world class universities leading the charge.
The movement is creating tremendous promise for people suffering with these debilitating diseases and a deep sense of accomplishment for those who have long sought to include psychedelics in scientific consideration as a viable treatment modality.
While psychedelics are expected to heal tens of millions globally and transcend the way we think about the mind and human consciousness, it is also creating unprecedented investment opportunities with the first IPOs happening earlier this year, and jurisdictions around the country are moving to decriminalize use and possession.
Our News section will keep readers informed with all of the latest industry updates with regard to research progress, investor news and cultural reform.
Majority of Canadians Support Access to Psilocybin; Psyc Firms Embrace Tech For Personalized Treatment; US Military Invests in Psychedelic Research
Rick Doblin, a leading force in America's psychedelic renaissance, imagines a world of "mass mental health" facilitated by formerly demonized drugs.
Marcus Capone, former Navy Seal, and wife, Amber, founded Veterans Exploring Treatment Solutions (VETS), a nonprofit that is partnered with MAPS
International team is researching and developing new class of drugs with fast-acting mental health benefits as psychedelics without effects of full-blown trip.
Mind Medicine Inc has said it is “rapidly advancing” its drug development pipeline and research activities since being publicly listed on March 3 this year.
New research asks, how does psilocybin create a feeling of ego dissolution, and what chemicals in the brain create our subjective sense of self?
Therapeutic psilocybin initiative will give Oregonians a chance to make it the first state in the country to legalize psychedelic mushrooms in clinical settings
The use of biomarkers to help doctors tailor doses for patients and improve treatment, while remote monitoring could widen access to psychedelics treatment.